{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-25-001570","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.022132+00:00","generated_at":"2026-05-16T20:09:36.537670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunic Q3 2025 net loss $25.6M; cash $35.1M; warns insufficient liquidity for 12 months","bullets":["Net loss of $25.6M ($0.13/share) vs $24.4M ($0.24/share) in Q3 2024; nine-month loss $77.9M.","Cash and equivalents $35.1M as of Sep 30, 2025; company states it lacks adequate liquidity to fund operations for 12 months without additional capital.","R&D expenses $20.0M, down from $21.4M; G&A $6.0M, up from $4.4M.","At ECTRIMS, presented CALLIPER data showing statistically significant 24-week confirmed disability improvement in progressive MS.","Received USPTO Notice of Allowance for patent covering vidofludimus calcium dose strengths for PMS; top-line ENSURE data expected by year-end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-25-001570","json":"https://secwatch.observer/filing/0001193805-25-001570.json","markdown":"https://secwatch.observer/filing/0001193805-25-001570.md","text":"https://secwatch.observer/filing/0001193805-25-001570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/0001193805-25-001570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001570/e664954_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:09:36.537670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}